Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $8.20

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.50.

Several research analysts have recently weighed in on RGLS shares. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $9.00 price target on shares of Regulus Therapeutics in a report on Thursday. Leerink Partners reaffirmed a “market perform” rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday. Canaccord Genuity Group reissued a “hold” rating and issued a $11.00 price target (down previously from $28.00) on shares of Regulus Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, March 14th. Finally, Jones Trading restated a “hold” rating and set a $7.00 price target (down previously from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RGLS. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $46,000. PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter worth approximately $95,000. Oppenheimer & Co. Inc. bought a new stake in shares of Regulus Therapeutics during the 1st quarter valued at $96,000. Velan Capital Investment Management LP purchased a new position in shares of Regulus Therapeutics during the 4th quarter valued at $111,000. Finally, JPMorgan Chase & Co. boosted its holdings in Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 52,059 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Price Performance

Shares of RGLS stock opened at $7.85 on Wednesday. Regulus Therapeutics has a 12-month low of $0.83 and a 12-month high of $8.20. The company has a 50 day moving average of $2.11 and a 200-day moving average of $1.66. The firm has a market cap of $520.01 million, a P/E ratio of -7.34 and a beta of 1.03.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, hitting the consensus estimate of ($0.20). During the same quarter in the previous year, the company posted ($0.40) earnings per share. As a group, equities analysts expect that Regulus Therapeutics will post -0.88 EPS for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.